7:58 AM
 | 
Jun 08, 2018
 |  BioCentury  |  Finance

Nimbus looks inward

Why Atlas sees value in Nimbus’ plan to keep some assets to itself

Nimbus plans to use a $65 million financing it raised on Tuesday to take programs deeper in development, refining its founding strategy of partnering its compounds early on.

Existing investor Atlas Venture led the round, which saw participation from all of Nimbus’ other existing investors: SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures and Schrödinger.

Since its founding in 2009, the computational chemistry company has used a business model in which its programs are housed in separate subsidiaries for the express purpose of making them easier to sell off early in the development process

Read the full 474 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >